Acute pharmacodynamic responses to sitagliptin:

Drug-induced increase in early insulin secretion in oral glucose tolerance test.

Amber L. Beitelshees PharmD[1] | Elizabeth A. Streeten MD[1] |

Zhinous Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] | Braxton D. Mitchell PhD[1] |

Alan R. Shuldiner MD[1] | May E. Montasser PhD[1] | Simeon I. Taylor MD[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Correspondence

Amber L. Beitelshees, Pharm D, MPH, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Email: abeitels@som.umaryland.edu

OR

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Email: staylor2@som.umaryland.edu

Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease (P30DK072488, P30DK079637, T32DK098107)

Trial registration: NCT05762744 (clinicaltrials.gov)

Study review and approval: Institutional Review Board of the University of Maryland Baltimore

Abstract

Aim: DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.

Methods: Sitagliptin (100 mg) was administered to 47 healthy volunteers. Several endpoints were measured to assess clinically relevant responses – including the effect of sitagliptin on glucose and insulin levels during an oral glucose tolerance test (OGTT).

Results: This pilot study confirmed that sitagliptin (100 mg) decreased the area under the curve for glucose during an OGTT (p=0.0003). Furthermore, sitagliptin promoted insulin secretion during the early portion of the OGTT as reflected by in increase in the ratio of plasma insulin at 60 min divided by plasma insulin at 30 min (T30:T60) from 0.87+/-0.05 to 1.62+/-0.36 mU/L (p=0.04). The magnitude of sitagliptin's effect on insulin secretion (as judged by the increase in the T30:T60 ratio for insulin) was correlated with the magnitude of sitagliptin-induced increase in the area under the curve for intact plasma GLP1 levels during the first hour of the OGTT. This study confirmed previously reported sex differences in glucose and insulin levels during an OGTT. Specifically, females exhibited higher levels of glucose and insulin at the 90-180 min time points. However, there did not appear to be significant differences in the magnitude of sitagliptin-induced changes in T30:T60 ratios for either glucose or insulin.

Conclusions: T30:T60 ratios for insulin and glucose during an OGTT provide useful indices to assess pharmacodynamic responses to DPP4 inhibitors.

1 | INTRODUCTION

The past two decades have been a golden age for discovery and development of diabetes drugs – including three classes of innovative drugs: dipeptidylpeptidase-4 (DPP4) inhibitors, GLP1 receptor agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors [1]. There are at least four approved DPP4 inhibitors: sitagliptin, saxagliptin, vildagliptin, and linagliptin [1]. Sitagliptin was the first drug in the class to be approved and remains the most widely prescribed dipeptidylpeptidase-4 (DPP4) inhibitor. According to FDA-approved prescribing information, sitagliptin decreases mean HbA1c by 0.7% when administered to type 2 diabetic patients who are inadequately controlled with metformin. However, there is substantial inter-individual variation in the magnitude of HbA1c-lowering. While some patients experience very modest HbA1c-lowering, others experience HbA1c-lowering of >1.5%.

While DPP4 inhibitors are not the most efficacious class of diabetes drugs with respect to HbA1c-lowering [1-4], they have the most favorable profiles with respect to safety and tolerability. Unlike GLP1 receptor agonists [1], they do not commonly cause nausea or vomiting. Unlike SGLT2 inhibitors [5], they are not associated with an increased risks of genital infections or ketoacidosis. Alogliptin is already available as a generic drug. When other DPP4 inhibitors experience loss of marketing exclusivity in the relatively near future, DPP4 inhibitors will represent an affordable oral antidiabetic drug that can be prescribed early in the course of type 2 diabetes to patients who are not adequately controlled on metformin. In this context, it would be desirable to be able predict which patients are likely to experience above-average glycemic responses to DPP4 inhibitors. For example, if a patient experiences above-average HbA1c-lowering (>0.7%) in response to a DPP4 inhibitor, that degree of glycemic improvement would provide substantial clinical benefit to the patient. According to GoodRx, a one-month supply of sitagliptin (100 mg) costs ~$550 in the US whereas a one-month supply of generic alogliptin (25 mg) is available for ~$150 (i.e., ~70% lower price). The price of generic DPP4 inhibitors is

projected to fall to levels comparable to generic sulfonylureas or metformin as a result of competition after sitagliptin and other DPP4 inhibitors experience loss of marketing exclusivity. In light of the high degree of safety and tolerability, generic DPP4 inhibitors have potential to displace generic sulfonylureas and generic pioglitazone in many patients' therapeutic regimens – especially if it becomes possible to identify individual patients likely to experience above-average HbA1c-lowering.

This manuscript describes an approach to assess the magnitude of an individual's acute pharmacodynamic response to sitagliptin by analyzing data from an oral glucose tolerance test (OGTT). Whereas sitagliptin does not exert a significant affect on the area under the curve (AUC) for glucose-stimulated insulin secretion, sitagliptin administration shifts the time course to earlier times. Similarly, sitagliptin significantly alters the time course for glucose levels during an OGTT. These data provide validation for a promising approach to conduct a pharmacogenomic study to identify genetic variants that are associated with pharmacodynamic responses to sitagliptin.

2 | METHODS

2.1 | Study population: recruitment and screening

The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the early 1700's. University of Maryland School of Medicine researchers have been studying genetic determinants of cardiometabolic health in this population since 1993. To date, ~10,000 Amish adults participated in one or more studies as part of the Amish Complex Disease Research Program (http://www.medschool.umaryland.edu/endocrinology/Amish-Research-Program/). The present study was a sub-study of a pilot study in healthy volunteers in which we investigated pharmacodynamic responses to exenatide [6]. A research nurse, accompanied by a member of the Amish community, made home visits to invite individuals to participate in the study. If they expressed interest, the study was explained in detail; potential participants were invited to sign an informed consent form. Thereafter, the research nurse obtained a medical history; measured height, weight and blood pressure; and obtained blood samples for screening laboratory tests (hematocrit, fasting plasma glucose, serum creatinine, serum AST, serum ALT, plasma TSH, and HbA1c).

2.2 | Study design: overview

Participants in the parent study (NCT05762744) were offered the opportunity to participate in this clinical trial investigating pharmacodynamic responses to sitagliptin. This sub-study was designed as a crossover study in which healthy individuals underwent a control oral glucose tolerance test (OGTT). After a washout period of at least one week, participants underwent a second OGTT. Two hours prior to the second OGTT, participants received sitagliptin (100 mg, p.o.). All procedures were reviewed and approved by the University of Maryland Baltimore IRB. On the days of the OGTTs, participants in the fasting state were transported to the Amish Research Clinic where heights, weights, and vital signs were measured. Participants were

weighed in a standardized manner while wearing a gown. Reproductive age women underwent a pregnancy test to exclude women who were pregnant. Fasting blood tests were obtained to measure fasting plasma glucose and lipid profile. OGTTs were conducted as described previously [7]. Two hours after receiving the intervention [either placebo or sitagliptin (100 mg, p.o.)], participants received oral glucose (75 g). Blood samples were obtained at 7 time points: 0, 30, 60, 90, 120, 150, and 180 minutes.

2.3 | Eligibility criteria

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent, at least 18 years old, and have BMI between 18-40 kg/m^2. Exclusion criteria are summarized in the Supplementary Appendix.

2.4 | Clinical chemistry

Processing of blood samples and laboratory methods are summarized in the Supplementary Appendix.

2.5 | Data and statistical analyses

We established two primary end points: sitagliptin's effect on area under the curve (AUC) for levels of (a) insulin and (b) glucose during the course of a 3-hour OGTT. We also established several secondary endpoints: sitagliptin's effect on AUC for intact GLP1, total GIP, and glucagon during the course of the first hour of an OGTT. After having reviewed the OGTT data, we established six exploratory end-points:

- *T30:T60 ratio for insulin*: the ratio of the insulin level at 30 min divided by the insulin level at 60 min in both the (a) control OGTT and (b) sitagliptin OGTT.

- *T30:T60 ratio for glucose*: the ratio of the glucose level at 30 min divided by the glucose level at 60 min in both the (c) control OGTT and (d) sitagliptin OGTT.

- *Drug effects*: (e) the ratio of the T30:T60 ratio for insulin in the sitagliptin OGTT divided by the T30:T60 ratio for insulin in the control OGTT; and (f) the ratio of the T30:T60 ratio for glucose in the sitagliptin OGTT divided by the T30:T60 ratio for glucose in the control OGTT.

Statistical significance was assessed using two-tailed Student's t-tests for paired data. Although a p-value of $p < 0.05$ was defined as the threshold for nominal statistical significance, a more stringent threshold (e.g., $p < 0.001$) may be appropriate to account for multiple comparisons.

3 | Results

3.1 | Disposition and adverse events

Disposition of participants and adverse events are summarized in Fig. S1. Fifty-nine individuals were enrolled in this clinical trial between June, 2016 - November, 2018. Forty-seven participants completed oral glucose tolerance tests (OGTT). Research participants' baseline characteristics are summarized in Table S1.

3.2 | Oral glucose glucose tolerance tests: impact of sitagliptin

Sitagliptin decreased the area under the curve (AUC) for glucose by 9% (p=0.0003) but did not significantly affect the AUC for insulin (Fig. 1). Nevertheless, sitagliptin appeared to change the shapes of the curves corresponding to time courses for both glucose and insulin – moving the peaks of the curves for both mean glucose and mean insulin from 60 min (placebo) to 30 min (post-sitagliptin). Accordingly, we calculated ratios of the levels of glucose or insulin at 60 min divided by the corresponding levels at 30 min (T30:T60) (Fig. 2AB). Sitagliptin increased the mean T30:T60 ratio for glucose from 0.93±0.02 to 1.11±0.04 (p=0.0005) and the mean T30:T60 ratio for insulin from 0.87±0.05 to 1.62±0.04 (p=0.04). We hypothesized that drug-induced increases in early insulin secretion at 30 min drive the subsequent decrease in glucose at 60 min. This hypothesis is supported by the observation that individual values of the T30:T60 ratio for glucose was correlated with individual values of the T30:T60 ratio for insulin (r=0.70, p<0.0001) (Fig. 2C). We observed substantial inter-individual variation in the magnitudes of sitagliptin's effect on levels of insulin and glucose (Fig. S2). Approximately 30% of participants experienced a numerical decrease in the value of the T30:T60 ratio for insulin after receiving sitagliptin. We hypothesize that these small numerical decreases were likely explained by experimental variation rather than a true "paradoxical" effect of sitagliptin. Similarly, approximately 30% of participants experienced a numerical decrease in the value of the

T30:T60 ratio for glucose after receiving sitagliptin. Among the individuals in whom sitagliptin was accompanied by increased T30:T60 ratios, the maximum drug effects were ~3-fold for glucose and ~20-fold for insulin.

3.3 | Biological variable affecting responses during OGTTs

Sex. Mean plasma levels of both glucose and insulin were higher in females than in females during the later time points in OGTTs (90-180 min) (Fig. 3). This sex difference was observed in both control OGTTs and sitagliptin OGTTs. Sitagliptin significantly increased mean T30:T60 ratios for glucose in both males and females (p=0.03). Sitagliptin significantly increased the mean T30:T60 ratio for insulin in males (p=0.01). In addition, the numerical value for the mean T30:T60 ratio for insulin was increased by sitagliptin in females (p=0.11). We did not observe significant differences between the magnitude of the drug effects on mean T30:T60 ratios for either glucose or inulin (Table S2).

Age. The variance in age accounted for 3% of the variation in T30:T60 ratios for glucose in control OGTTs and 14% of the variance in T30:T60 ratios for glucose in sitagliptin OGTTs (Fig. S3). The variance in age accounted for 4% of the variation in T30:T60 ratios for insulin in control OGTTs and 12% of the variance in T30:T60 ratios for insulin in sitagliptin OGTTs (Fig. S3).

BMI. The variance in BMI accounted for 4% of the variation in T30:T60 ratios for glucose in control OGTTs and 17% of the variance in T30:T60 ratios for glucose in sitagliptin OGTTs (Fig. S4). The variance in age accounted for 0.04% of the variation in T30:T60 ratios for insulin in control OGTTs and 0.5% of the variance in T30:T60 ratios for insulin in sitagliptin OGTTs (Fig. S4).

3.4 | Impact of sitagliptin on secretion of GLP1, GIP, and glucagon

Sitagliptin increased mean levels of intact GLP1 at all time points (0, 30, and 60 min) and induced a 2.3-fold increase in the mean AUC for intact GLP1 from 7.0±0.7 to 15.8±1.5 pmol-hr/L (p=3x10^{-8}) (Fig. 4A). Sitagliptin increased the mean AUC for glucagon by 66% from 3.74±0.27 to 6.21±0.46 (p=7x10^{-9}) (Fig. 4C). The increase in mean AUC for glucagon is primarily a reflection of an increase in mean glucagon levels at time zero. Sitagliptin did not affect mean total GIP levels at time zero but decreased mean AUC for total GIP by 24% (Fig. 4B). We did not conduct assays that specifically measure levels of intact GIP.

We hypothesized that drug-induced increases in GLP1 secretion contributed to the drug-induced increase in insulin secretion during the OGTT. This hypothesis is supported by the observation that individual values of the drug-effect on insulin levels was correlated with individual values of the drug effect on GLP1 levels (r=0.29, p<0.04) (Fig. 5).

As this clinical trial was a sub-study within our pilot clinical trial of pharmacodynamic responses to exenatide [6], we inquired whether responses to sitagliptin were correlated with responses to exenatide. Forty-five participants underwent both frequently sampled intravenous glucose tolerance tests in our exenatide clinical trial and oral glucose tolerance tests in our sitagliptin clinical trial. The variance in exenatide's effect to increase first phase insulin secretion accounted for only 0.7% of the variance in sitagliptin's effect to increase T30:T60 for insulin (r=0.084) (Fig. S5). The variance in exenatide's effect to accelerate the rate of glucose disappearance accounted for only 0.007% of the variance in sitagliptin's effect to increase T30:T60 for insulin (r=0.0084) (Fig. S5).

4 | Discussion

Our clinical trial demonstrated that sitagliptin (100 mg) decreased mean AUC for glucose by 9% when administered to healthy volunteers two hours prior to initiation of an OGTT (Fig. 1). Similarly, Herman et al. [8] reported that sitagliptin (200 mg) decreased mean weighted averages for *incremental* glucose by 18% when administered to patients with type 2 diabetes two hours before an OGTT. Whereas Herman et al. [8] reported that sitagliptin (200 mg) increased mean weighted averages for insulin and C-peptide by ~20% in patients with type 2 diabetes, our clinical trial did not detect a significant effect of sitagliptin (100 mg) on mean AUC for insulin in healthy volunteers. Both Herman et al. [8] and we demonstrated that sitagliptin induced an approximately twofold increase in levels of intact GLP1. Herman et al. [8] demonstrated that sitagliptin increased levels of active GIP while inducing a modest decrease in total levels of GIP. Although we did not measure levels of intact GIP, we confirmed their observation that sitagliptin decreased mean AUC for GIP by 24%. As hypothesized by Herman et al., it seems likely that sitagliptin-induced increases in intact GLP1 and/or intact GIP mediate the effect of drug to improve glucose tolerance. Whereas Herman et al. [8] reported a 14% decrease in glucagon levels, we observed a highly significant 66% increase in mean AUC for glucagon in response to sitagliptin (100 mg). Although it is unclear how to explain the difference between data in healthy volunteers versus patients with type 2 diabetes, it is noteworthy that diabetes is associated with dysregulation of glucagon secretion [9-11]. Mathematical modeling of meal tolerance tests demonstrated that vildagliptin increased insulin secretion (primarily in response to breakfast and lunch rather than dinner) without altering glucose sensitivity of the β-cells [12,13]. Alsalim at al. [14] reached similar conclusions when mathematical modeling was applied to analysis of the effect of sitagliptin on meal tolerance tests conducted either in healthy volunteers or patients with type 2 diabetes. Just as we observed that sitagliptin induced a small effect to decrease mean AUC for glucose (p=0.0003) without altering mean AUC for insulin in healthy volunteers, Alsalim et al.

similarly observed that sitagliptin decreased mean AUC for glucose by 14% in both healthy volunteers and patients with type 2 diabetes without inducing a statistically significant effect on mean AUCs for insulin or C-peptide.

How can one explain the apparent paradox that sitagliptin improved glucose tolerance (i.e., significantly decreased the mean AUC for glucose) without increasing mean AUC for insulin? Although sitagliptin (100 mg) did not alter mean glucose levels at 0 or 30 min, sitagliptin decreased glucose levels at later time points in the OGTT – most notably at 60 and 90 min. Moreover, although sitagliptin increased mean insulin levels at 30 min, mean insulin levels at 60 min were actually lower for the sitagliptin OGTTs than for the control OGTTs. Mean AUCs were unchanged because the lower levels at 30 min are balanced out by higher levels at 60 min. We hypothesize that the increase in early insulin secretion (i.e., at 30 min) may drive the subsequent decrease in mean glucose levels (e.g., at 60 and 90 min). This could be viewed as the mirror image of the natural history of type 2 diabetes, in which early insulin secretion (first phase) is selectively lost early in the natural history of the disease. In that context, a selective increase in early insulin secretion addresses the pathophysiology of type 2 diabetes. Based on our observations, we hypothesized that ratios of insulin levels at 30 min divided by insulin levels at 60 min would provide a useful index of the shape of the curves for the time course of insulin secretion. Because sitagliptin increased mean insulin levels at 30 min and decreased mean insulin levels at 60 min (Fig. 1B), sitagliptin administration induced a 1.9-fold increase (p=0.04) in the mean T30:T60 ratio for insulin (Fig. 2B). Similarly, because sitagliptin decreased mean glucose levels at 60 min (Fig. 1A), sitagliptin induced a 19% increase (p=0.0005) in the T30:T60 ratio for glucose (Fig. 2A).

The principal objective of our study was to validate pharmacodynamic endpoints for a future pharmacogenomic study of individual responses to a single administration of sitagliptin. Our observations suggest that T30:T60 ratios for glucose and insulin would provide sensitive

endpoints for such a pharmacogenomic study. Whereas administration of sitagliptin did not change the AUC for insulin in an OGTT, sitagliptin elicited a substantial (90%) increase in the mean T30:T60 ratio for insulin. Furthermore, we observed substantial inter-individual variation in the magnitude of sitagliptin's effect on T30:T60 ratios – ranging from little or no effect on either T30:T60 ratio to a 175% increase in the T30:T60 ratio for glucose and a >10-fold increase in the T30:T60 ratio for insulin (Fig. 3). Furthermore, the variance in the sitagliptin-induced increase in the T30:T60 ratio for insulin accounted for ~50% of the variance in the sitagliptin-induced increase in the T30:T60 ratio for glucose (Fig. 2) – suggesting that T30:T60 ratios provide physiologically relevant indices of insulin secretion and insulin action. We hypothesize that inter-individual variation in insulin sensitivity and/or glucose effectiveness may also contribute to the unexplained variance in the T30:T60 ratio for glucose that is not explained by inter-individual variation in the T30:T60 ratio for insulin. Interestingly, we confirmed the previously reported sex-asssociated difference in responses during an OGTT [15] , which was attributed to slower absorption of orally administered glucose in females as compared to males. Thus, it will be important to adjust for sex as a covariate when conducting a GWAS searching for genetic variants associated with the response to sitagliptin.

Type 2 diabetes is a progressive disease – with the impairment in beta cell insulin secretion becoming more severe over time [2,16]. For example, although first line therapy with metformin may provide acceptable metabolic control early in the course of the disease, it is often necessary to add one or more drugs to restore acceptable metabolic control [1,2,16,17]. Physicians have quite a number of options when selecting a second drug to prescribe for patients who are inadequately controlled on metformin monotherapy – including, DPP4 inhibitors, SGLT2 inhibitors, GLP1R agonists, sulfonylureas, and pioglitazone among others [1,2,17,18]. Pharmacogenomics offers potential to predict each individual's response to specific diabetes drugs – thereby guiding the choice of optimal therapy for each patient. On average, DPP4

inhibitors provide slightly less mean HbA1c-lowering than several other classes of diabetes drugs [1-3]. However, if a physician could predict that an individual patient would experience above average HbA1c-lowering in response to a DPP4 inhibitor, this would increase the attractiveness of the clinical profile for a DPP4 inhibitor for that patient. The impact of a precision therapeutics approach would be magnified if it were possible to apply genetic information to compare the predicted efficacies of several drug classes for each individual patient. This logic provides a strong rationale for conducting pharmacogenomic research in the most important classes of diabetes drugs – including, DPP4 inhibitors, SGLT2 inhibitors, and GLP1R agonists [1,17,19]. In this context, it is noteworthy that many of our research participants in this clinical trial underwent studies to assess pharmacodynamic responses to both sitagliptin and exenatide. Interestingly, the variance in responses to exenatide accounted for <1% of the variance in responses to sitagliptin (Fig. S2). This observation suggests that some patients might experience above average responses to a DPP4 inhibitor but below average responses to a GLP1R agonists. Although a substantial investment will be required to fully realize the potential pharmacogenomics and precision therapeutics, such an approach has the potential to transform the approach to designing therapeutic regimens for patients with type 2 diabetes.

<u>AUTHORS' CONTRIBUTIONS</u>

<u>Conception of the clinical trial and PIs for grants</u>: ALB, SIT

<u>Acquisition and analysis of data</u>: ALB, H-RC, MEM, EAS, SIT, HBW, ZSY

<u>Establishment of Old Order Amish genotypedatabase</u>: BDM, ARS

<u>Preparation of first draft of manuscript</u>: SIT

<u>Revising and approving final version of manuscript</u>: all authors

<u>Accountability for all aspects of work</u>: ALB and SIT

Competing Interests

SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an employee of Regeneron Genetics Center. BDM and MEM receive grant support from Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support from funds provided by RGC. ALB, ZSY, and HRC declare no competing interests.

FIGURE 1. Sitagliptin increases area under the curve (AUC) for insulin levels as a function of time in an oral glucose tolerance test (OGTT). Forty-eight participants underwent a control 3-hour OGTT (75 grams of glucose) (depicted by gray circles in panels A and B and gray bars in panels C and D). One week later, two hours after having received a single administration of sitagliptin (100 mg, p.o.), participants underwent a second 3-hour OGTT (depicted by black squares in panels A and B and black bars in panels C and D). Data on glucose levels are presented in panels A and C. Data on insulin levels are presented in panels B and D. Data are expressed as means ± SEM. p-values (panels C and D) were calculated using a two-tailed Student's t-test for paired data.

FIGURE 2. Sitagliptin increases early insulin secretion and improves glucose tolerance during

an OGTT. Data from FIG. 1 were reanalyzed by calculating ratios were calculated by dividing

the concentrations of glucose (panel A) and insulin (panel B) at 30 min by the corresponding

concentrations at 60 minutes (T30:T60 ratio). Gray bars correspond to data from the control

OGTTs (panels A and B); black bars correspond to data from the sitagliptin OGTTs (panels A

and B). Data are expressed as means ± SEM and p-values (panels A and B) were calculated

using a two-tailed Student's t-test for paired data. Panel C depicts a graph of individual values of

the logarithms of the T30:T60 ratio for glucose as a function of the logarithms of corresponding

T30:T60 ratios for insulin.

FIGURE 3. Sex as a biological variable: sex-differences in responses to oral glucose. Data from Figs. 1A and 1B were re-analyzed after stratification according to the sex of the participant. Data on glucose levels are plotted in Panel A (control OGTT) and Panel B (Sitagliptin OGTT). Data on insulin levels are plotted in Panel D (Control OGTT) and Panel E (Sitagliptin OGTT). Data from Figs. 2A and 2B were re-analyzed after stratification according to the sex of the participant. Data on T:30 ratios for glucose and insulin are plotted in Panel C and F, respectively. Data are presented as means SEM. P-values were calculated using a two-tailed Student's t-test for paired data.

FIGURE 4. Effects of sitagliptin on area under the curve (AUC) for levels of intact dGLP1, total GIP, and glucagon as a function of time in an oral glucose tolerance test (OGTT). Time courses are depicted for GLP1 (panel A), GIP (panel B), and glucagon (panel C). Areas under the curve are depicted for GLP1 (panel D), GIP (panel E), and glucagon (panel F). Data are expressed as means ± SEM. p-values (panels C and D) were calculated using a two-tailed Student's t-test for paired data.

FIGURE 5. Effects of sitagliptin on insulin secretion are correlated with the magnitude of sitagliptin's effects on levels of intact GLP1. Individual values of the logarithm of the T30:T60 ratio for insulin are plotted as a function of the logarithms of individual values of the effect of sitagliptin on the AUC for intact GLP1.

REFERENCES

1. Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest.* 2021;131(2) doi: 10.1172/JCI142243

2. Nathan DM, Lachin JM, Balasubramanyam A, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. *N Engl J Med.* 2022;387(12):1063-1074.

3. Deng Y, Polley EC, Wallach JD, et al. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. *BMJ.* 2022;379:e070717.

4. Deng Y, Polley EC, Wallach JD, Herrin J, Ross JS, McCoy RG. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial. *BMJ Med.* 2023;2(1):e000419.

5. Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. *Diabetes.* 2019;68(6):1109-1120.

6. Taylor SI, Montasser ME, Yuen AH, et al. Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness. *Diabetes Obes Metab.* 2023;25(9):2586-2594.

7. Hsueh WC, Mitchell BD, Aburomia R, et al. Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study. *Diabetes Care.* 2000;23(5):595-601.

8. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2006;91(11):4612-4619.

9. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. *Diabetes Obes Metab.* 2011;13 Suppl 1:126-132.

10. Haedersdal S, Andersen A, Knop FK, Vilsboll T. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. *Nat Rev Endocrinol.* 2023;19(6):321-335.

11. Brooks EP, Sussel L. Not the second fiddle: alpha cell development, identity, and function in health and diabetes. *J Endocrinol.* 2023;258(2).

12. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2005;90(8):4888-4894.

13. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. *J Clin Endocrinol Metab.* 2008;93(1):103-109.

14. Alsalim W, Goransson O, Carr RD, et al. Effect of single-dose DPP-4 inhibitor sitagliptin on beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects. *Diabetes Obes Metab.* 2018;20(4):1080-1085.

15. Anderwald C, Gastaldelli A, Tura A, et al. Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. *J Clin Endocrinol Metab.* 2011;96(2):515-524.

16. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. *Diabetes.* 2011;60(5):1552-1560.

17. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2022;45(11):2753-2786.

18. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. *Diabetes Care.* 2021;44(2):433-439.

19. Chung WK, Erion K, Florez JC, et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43(7):1617-1635.

<u>Supplementary Appendix</u>

Acute pharmacodynamic responses to sitagliptin:

Drug-induced increase in early insulin secretion in oral glucose tolerance test.

Amber L. Beitelshees PharmD[1] | Elizabeth A. Streeten MD[1] |

Zhinous Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] | Braxton D. Mitchell PhD[1] |

Alan R. Shuldiner MD[1] | May E. Montasser PhD[1] | Simeon I. Taylor MD[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

[2] Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and

Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,

Baltimore, MD 21201, USA

Email: staylor2@som.umaryland.edu

Funding information

American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and

Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

<u>Table of Contents</u>

1 | Exclusion Criteria

- Known allergy to exenatide

- History of diabetes, random glucose >200 mg/dL, or HbA1c $\geq$ 6.5%

- Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judged would make interpretation of the results difficult or increase the risk of participation

- Seizure disorder

- Pregnant by self-report or known pregnancy within 3 months of the start of study

- Currently breast feeding or breast feeding within 3 months of the start of the study

- Estimated glomerular filtration rate <60 mL/min/1.73m^2

- Hematocrit <35%

- Liver function tests greater than 2 times the upper limit of normal

- Abnormal TSH

- History of pancreatitis or pancreatic cancer. Personal or family history of medullary carcinoma of the thyroid.

2 | Oral glucose tolerance tests (OGTTs)

After an overnight fast, participants were transported to the Amish Research Clinic where

OGTTs were performed (1, 2) as described previously [REF]. Briefly, glucose (75 g, p.o.) was

administered; blood samples were obtained at the following seven time points: 0, 30, 60, 90,

120, 150, and 180 min. Sitagliptin (100 mg, p.o.) was administered 2 hrs prior to the second

OGTT. Plasa levels of glucose and insulin were measured in blood samples for all seven time

points. Plasma levels of intact GLP1, total GIP, and glucagon were measured in blood samples

for the first three time points (0, 30, and 60 min).

3 | Clinical Chemistry

Screening blood samples were obtained by a research nurse during home visits and collected in test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for measurement of fasting plasma glucose; red top tube for collecting serum samples. After placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay. Blood samples for OGTTs were collected in EDTA-containing purple top tubes for measurement of plasma insulin and in EDTA/oxalate-containing gray top tubes for measurement of plasma glucose. Aprotinin was added to plasma samples for glucagon assays. A DPP4 inhibitor (Millipore) was added to plasma samples for assays of GLP1 and GIP. Glucose was measured in duplicate using a YSI glucose analyzer. Insulin was assayed in duplicate following the manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc. The following kits were used for assays of other peptides: intact GLP1 (Millipore #EGLP-35K), total GIP (Millipore #EXHGIP-54K), and glucagon (Mercodia #10-1271-01).

82 **Table S1. Demographics and baseline characteristics of study population**

Mean ± SEM (range)	Males	Females	Total
N (sample size)	27	20	47
Age (years)	44.3 ± 2.2	51.8 ± 2.2	47.5 ± 1.6
BMI (kg/m^2)	27.5 ± 0.7	28.7 ± 0.8	28.0 ± 0.5
HbA1c (%)	5.49 ± 0.07	5.59 ± 0.07	5.53 ± 0.05
Serum creatinine (mg/dL)	0.90 ± 0.02	0.74 ± 0.02	0.83 ± 0.02
eGFR (mL/min/1.73 m^2)	101.0 ± 2.5	94.1 ± 3.6	98.0 ± 2.1
Hematocrit (%)	43.8 ± 0.5	39.0 ± 0.5	41.8 ± 0.5
Aspartate amino transferase (U/L)	18.5 ± 0.9	17.4 ± 0.9	18.0 ± 0.6
Alanine amino transferase (U/L)	20.7 ± 1.7	17.3 ± 1.2	19.3 ± 1.0
TSH (mIU/L)	1.82 ± 0.20	1.81 ± 0.22	1.82 ± 0.14

TABLE S2. Effect of sitagliptin on T30:T60 ratios for glucose and insulin: data stratified

based on self-identified sex. The magnitude of drug effects were calculated by dividing the

T30:T60 ratio during the sitagliptin OGTT by the corresponding value for the control OGTT.

Data are expressed as means ± SEM for 47 participants (27 males and 20 females). P-values

were calculated using two-tailed Student's t-test for paired data for the T30:T60 ratio for glucose

and the log(T30:T60 ratio for insulin).

Effect of sitagliptin	Males	Females	p-value
T30:T60 ratio (glucose)	1.26 ± 0.08	1.16 ± 0.06	0.36
T30:T60 ratio (insulin)	2.44 ± 0.82	1.46 ± 0.26	0.35
N	27	20	

TABLE S3. Association of self-identified sex with areas-under-the-curve (AUC) for

glucose in oral glucose tolerance test. Areas-under-the-curve for glucose and insulin were

calculated using the trapezoidal rule. Data are presented as means ± SEM. p-values were

calculated using two-tailed Student's t-test for either unpaired (association with sex) or paired

data (effect of sitagliptin).

A. Association with sex

AUC	Treatment	Males	Females	p-value (for assoc. with sex)
Glucose	Control	2393 ± 72	2673 ± 94	0.02
Glucose	Sitagliptin	2181 ± 66	2465 ± 94	0.01
Insulin	Control	526 ± 45	666 ± 52	0.06
Insulin	Sitagliptin	501 ± 48	670 ± 72	0.05
N		27	20	

B. Effect of sitagliptin

AUC	Sex	Control	Sitagliptin	p-value (for effect of sitagliptin)
Glucose	Male	2393 ± 72	2181 ± 66	0.0002
Glucose	Female	2673 ± 94	2465 ± 94	8.3×10^{-10}
Insulin	Male	526 ± 45	501 ± 48	0.61
Insulin	Female	666 ± 52	670 ± 72	0.95
N		27	20	

Figure S1. CONSORT diagram summarizing disposition of research participants. Seventy-

one individuals underwent screening for the clinical trial between August, 2016 – November,

2018. Twelve enrollees were excluded for the following reasons (Fig. S1): low hematocrit (N=1),

abnormal TSH levels (N=5), abnormal liver function tests (N=1), family history of medullary

carcinoma of the thyroid (N=1), primary hyperparathyroidism (N=1), low eGFR (N=1), poor

venous access (N=1), and treatment with warfarin (N=1). Thus, 59 individuals were judged to be

eligible for the clinical trial. Three individuals changed their minds and withdrew from the study

after providing informed consent but before undergoing an intravenous glucose tolerance test;

technical challenges with establishing venous access led to withdrawal of an additional

participant. Fifty-five participants completed two oral glucose tolerance tests. Eight individuals

were excluded from the database because of missing data. Thus, data from 47 individuals

comprised the final database for the analyses. There were 13 reported adverse events of mild

severity. One participant reported feeling light-headed or "dizzy". There were six events in which

a participant's plasma glucose (determined using a glucometer) was <70 mg/dL during the

course of an OGTT. Four participants reported headaches; one reported diarrhea; and one

reported nausea.

118
119

120 **FIGURE S1. CONSORT Diagram**

122
123

124 **FIGURE S2. c.** Indices for the effects of sitagliptin were calculated as the ratios of T30:T60 ratio

125 from the sitagliptin OGTT divided by the corresponding ratio from the control OGTT. Analyses

126 were conducted on logarithmically transformed ratios of drug effects for sitagliptin on glucose

127 (panel A) and insulin (panel B). The graphs depict the numbers of individuals whose log(drug

128 effects) fall into the ranges depicted on the respective x-axes.

FIGURE S3. Association of age with responses to sitagliptin. This Figure presents an
analysis of associations of age with data on T30:T60 ratios for glucose (panels A-C) and insulin
(panels D-F). Data for males and females are depicted by black circles or gray squares,
respectively. Data for T30:T60 ratios for glucose are plotted on a linear scale; data for T30:T60
ratios for insulin are plotted on a logarithmic scale. Each panel includes the least squares linear
fit to the data. Correlation coefficients (r) were calculated using the data corresponding to
T30:T60 ratios for glucose (panels A and B) or logarithms of the T30:T60 ratios for insulin
(panels D and E). The drug effect for T30:T60 ratio for glucose was calculated as the ratio of the
T30:T60 ratio for glucose in the control OGTT divided by the T30:T60 ratio in the sitagliptin
OGTT (panel C). The drug effect for T30:T60 ratio for insulin was calculated as the difference
when the T30:T60 ratio for insulin in the sitagliptin OGTT subtracted from the T30:T60 ratio in
the control OGTT (panel F).

FIGURE S4. Association of BMI with responses to sitagliptin. This Figure presents an

analysis of associations of age with data on T30:T60 ratios for glucose (panels A-C) and insulin

(panels D-F). Data for males and females are depicted by black circles or gray squares,

respectively. Data for T30:T60 ratios for glucose are plotted on a linear scale; data for T30:T60

ratios for insulin are plotted on a logarithmic scale. Each panel includes the least squares linear

fit to the data. Correlation coefficients (r) were calculated using the data corresponding to

T30:T60 ratios for glucose (panels A and B) or logarithms of the T30:T60 ratios for insulin

(panels D and E). The drug effect for T30:T60 ratio for glucose was calculated as the ratio of the

T30:T60 ratio for glucose in the control OGTT divided by the T30:T60 ratio in the sitagliptin

OGTT (panel C). The drug effect for T30:T60 ratio for insulin was calculated as the difference

when the T30:T60 ratio for insulin in the sitagliptin OGTT subtracted from the T30:T60 ratio in

the control OGTT (panel F).

FIGURE S5. Correlation of pharmacodynamic effects of sitagliptin with

pharmacodynamic effect exenatide. The effect of sitagliptin on log(T30:T60 for insulin) is

plotted as a function of the effect of exenatide on log(1st phase insulin secretion) is plotted in the

upper panel. The effect of sitagliptin on T30:T60 for glucose is plotted as a function of the effect

of exenatide on the glucose disappearance rate is plotted in the lower panel. Data on

pharmacodynamic effects of exenatide are based on data from the parent clinical trial with

exenatide [REF]. Correlation coefficients were calculated using software provided in Microsoft

EXCEL.

REFERENCES
173
174
175